GlassScriptPhysician profile
Abdul M Khan
NPI 1447410485
$2,657.56
in general payments reported to CMS, 2019-2025
19 companies · $183 in 2025
The $183 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $581 · 2021: $148 · 2022: $263 · 2023: $382 · 2024: $227 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $791.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $748.38 | 2019-2025 | Trelegy Ellipta, Nucala, Benlysta |
| Astrazeneca Pharmaceuticals LP | $648.08 | 2019-2024 | Fasenra |
| Amgen INC. | $251.62 | 2019-2024 | Repatha, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.55 | 2019-2023 | Ofev |
| Alkermes, INC. | $134.67 | 2022-2025 | Aristada, Lybalvi |
| Genentech USA, INC. | $124.83 | 2019 | |
| La Jolla Pharmaceutical Company | $114.89 | 2019 | |
| Janssen Pharmaceuticals, INC | $110.22 | 2019-2022 | |
| Pfizer INC. | $55.83 | 2019-2023 | |
| Genzyme Corporation | $45.59 | 2023 | |
| Kerecis Limited | $35.82 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Blue Earth Diagnostics | $34.60 | 2024 | |
| Philips North America LLC | $29.90 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $19.74 | 2024 | Dupixent |
| Novo Nordisk INC | $19.61 | 2024 | Ozempic, Rybelsus |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.42 | 2023 | |
| Electromed, INC. | $16.20 | 2023 | Smartvest |
| Janssen Biotech, INC. | $14.73 | 2023 | Stelara, Simponi Aria, Simponi |
| Kiniksa Pharmaceuticals, LTD. | $13.88 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.